{"panels":[{"content":{"params":{"text":"

First, ownership of biosamples collected in each country needs to be clearly defined. Participants should be informed about who will own their samples once collected, whether it is the institution, the biobank, or a third party. Additionally, the ownership of data derived from these samples must be transparent, with clear agreements on how it will be stored, shared, and used, especially in cross-border collaborations.<\/p>\n\n

<\/p>\n\n

Second, intellectual property issues must be clarified. Any discoveries, such as genetic markers or predictive models developed from the research, could have significant commercial and medical value. Fair agreements must ensure that both countries benefit from potential commercial gains, particularly ensuring that Country Y, as a lower-income nation, is not excluded from the benefits of research originating from its biosamples and data. Equitable sharing of benefits and clear IP agreements are essential to avoid exploitation.<\/p>\n\n

<\/p>\n\n

Clear policies must be established regarding researcher access to biobank materials. Only researchers with approved projects and appropriate ethical oversight should be granted access. Issues of ownership of biological materials and IP arising from research need careful consideration. Samples typically remain the property of the biobank, but researchers may have access to data derived from those samples. Any IP developed from the research, for example, predictive models, genetic markers should be subject to collaborative agreements that ensure equitable sharing of benefits, especially between Country X and Country Y. It is essential to prevent exploitation, ensuring that all collaborators, including participants, benefit from research outcomes.<\/p>\n"},"library":"H5P.AdvancedText 1.1","subContentId":"3f950fe1-5da3-4d66-b0ae-ecceb6958f47","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"title":"Video Transcript"}],"hTag":"h2"}

Breadcrumb

Considering Ownerships